Silmitasertib (CX-4945)

For research use only. Not for use in humans.

目录号：S2248

Silmitasertib (CX-4945) Chemical Structure

CAS No. 1009820-21-6

Silmitasertib (CX-4945)是有效的，选择性CK2(casein kinase 2)抑制剂，无细胞试验中IC50为1 nM,对 Flt3, Pim1 和 CDK1作用效果稍弱(细胞试验中没有活性)。Silmitasertib可诱导自噬并促进细胞凋亡。Phase 1/2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2381.77	现货
1mg	RMB 1040.13	现货
2mg	RMB 1418.29	现货
5mg	RMB 2604.97	现货
50mg	RMB 7289.1	现货
100mg	RMB 10401.33	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Silmitasertib (CX-4945)发表文献79篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):27

PubMed: 33712563 ( click the link to review the publication )

Cells, 2021, 10(2)338

PubMed: 33562780 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2289

PubMed: 32385263 ( click the link to review the publication )

Diabetes, 2020, db191186

PubMed: 32540877 ( click the link to review the publication )

Fertil Steril, 2020, 113(5):1067-1079 e5

PubMed: 32386617 ( click the link to review the publication )

Curr Biol, 2020, S0960-9822(20)31413-5

PubMed: 33065005 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(13):E4668

PubMed: 32630015 ( click the link to review the publication )

J Anim Sci Biotechnol, 2020, 8;11:31

PubMed: 32292585 ( click the link to review the publication )

Transl Oncol, 2020, 13(1):70-78

PubMed: 31810002 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0227340

PubMed: 31910234 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Mol Cell, 2019, 74(3):571-583

PubMed: 30898438 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

EMBO J, 2019, 38(23):e101409

PubMed: 31696965 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(27):13374-13383

PubMed: 31209037 ( click the link to review the publication )

Cell Rep, 2019,

PubMed: 31825822 ( click the link to review the publication )

EBioMedicine, 2019, 49:106-117

PubMed: 31668570 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 18;38(1):131

PubMed: 30885251 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0657-5

PubMed: 31776458 ( click the link to review the publication )

Addict Biol, 2019, 10.1111/adb.12808

PubMed: 31364211 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(4):987-1001

PubMed: 30610108 ( click the link to review the publication )
Cell Cycle, 2019, 18(24):3472-3490

PubMed: 31713447 ( click the link to review the publication )

Oncol Rep, 2019, 10.3892/or.2019.7187

PubMed: 31173270 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:6125068

PubMed: 31531359 ( click the link to review the publication )

Biol Res, 2019, 52(1):22

PubMed: 30992075 ( click the link to review the publication )

Int J Radiat Biol, 2019, 10.1080/09553002.2019.1642531

PubMed: 31290713 ( click the link to review the publication )

Oncol Lett, 2019, 18(4):3845-3856

PubMed: 31579410 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5109-5124

PubMed: 29850896 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):84

PubMed: 30420689 ( click the link to review the publication )

J Biol Chem, 2018, 293(8):2990-3002

PubMed: 29326167 ( click the link to review the publication )

Biomed Pharmacother, 2018, 106:403-410

PubMed: 29966986 ( click the link to review the publication )

Biomed Pharmacother, 2018, 98:357-363

PubMed: 29275177 ( click the link to review the publication )

Biochemistry (Mosc), 2018, 83(11):1380-1387

PubMed: 30482149 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

Oncotarget, 2018, 9(18):14597-14607

PubMed: 29581866 ( click the link to review the publication )

Cell Rep, 2017, 18(13):3167-3177

PubMed: 28355568 ( click the link to review the publication )

Exp Mol Med, 2017, 49(9):e375

PubMed: 28883547 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16367

PubMed: 29180680 ( click the link to review the publication )

J Cell Biochem, 2017, 118(8):2463-2473

PubMed: 28133777 ( click the link to review the publication )

Pancreas, 2017, 46(4):575-581

PubMed: 28196025 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 28542269 ( click the link to review the publication )

Heliyon, 2017, 3(6):e00318

PubMed: 28649667 ( click the link to review the publication )

Pharmaceuticals (Basel), 2017, 10(1)E5

PubMed: 28045438 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2016, 113(36):10145-50

PubMed: 27555590 ( click the link to review the publication )

Cancer Res, 2016, 76(9):2675-86

PubMed: 26980766 ( click the link to review the publication )

J Cell Biol, 2016, 212(3):281-8

PubMed: 26811421 ( click the link to review the publication )

Dis Model Mech, 2016, 9(8):839-48

PubMed: 27483355 ( click the link to review the publication )

Cell Signal, 2016, 28(2):23-31

PubMed: 26577526 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1323-40

PubMed: 26593250 ( click the link to review the publication )

Pharmaceuticals (Basel), 2016, 10(1)E2

PubMed: 28036027 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26793-805

PubMed: 27050366 ( click the link to review the publication )

eNeuro, 2016, 3(6)ENEURO.0092-16.2016

PubMed: 27957526 ( click the link to review the publication )

Tumour Biol, 2016, 37(6):8293-304

PubMed: 26729194 ( click the link to review the publication )

Oncotarget, 2016, 7(52):87361-87372

PubMed: 27888634 ( click the link to review the publication )

Nat Commun, 2015, 6:7227

PubMed: 26085373 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):751-61

PubMed: 25449433 ( click the link to review the publication )

J Mol Cell Cardiol, 2015, 84:191-9

PubMed: 25937534 ( click the link to review the publication )

Biochim Biophys Acta, 2015, 1853(10 Pt A):2207-16

PubMed: 26025678 ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 61C:81-89

PubMed: 25680545 ( click the link to review the publication )

Mol Cell Biochem, 2015, 404(1-2):103-12

PubMed: 25805179 ( click the link to review the publication )

Anal Biochem, 2015, 468:4-14

PubMed: 25233003 ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1537-42

PubMed: 25750308 ( click the link to review the publication )

Bioconjug Chem, 2015, 26(12):2324-35

PubMed: 26559659 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Nat Immunol, 2015, 16(3):267-75

PubMed: 25599562 ( click the link to review the publication )

Nat Commun, 2014, 5:3393

PubMed: 24569712 ( click the link to review the publication )

Leukemia, 2014, 28(3):543-53

PubMed: 24253024 ( click the link to review the publication )
Cell Death Dis, 2014, 5:e1551

PubMed: 25476899 ( click the link to review the publication )

Cell Signal, 2014, 26(12):2809-2817

PubMed: 25194820 ( click the link to review the publication )

Cell Signal, 2014, 26(7):1567-75

PubMed: 24686080 ( click the link to review the publication )

FEBS Lett, 2014, 9(4):e94978

PubMed: 24743259 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Mol Cell Biochem, 2013, 384(1-2):71-82

PubMed: 23963994 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1830(4):2938-45

PubMed: 23287549 ( click the link to review the publication )

产品安全说明书

Casein Kinase抑制剂选择性比较

生物活性

产品描述

特性

CX-4945是促进人类临床实验的CK2的第一个口服生物相容性小分子抑制剂。

靶点

CK2 ^[1]
(Cell-free assay)

1 nM

体外研究

CX-4945是CK2特异的抑制剂，它只抑制238种激酶中的7种并且在0.5 μM浓度时它的抑制率超过90%，这是CK2的IC50的500多倍。虽然在无细胞系统中CX-4945抑制FLT3, PIM1和CDK1的IC50分别为35 nM, 46 nM和56 nM，但是在细胞基础上的功能实验中10 μM的CX-4945对FLT3, PIM1和 CDK1抑制作用不强。CX-4945有广谱的抗恶性细胞增生活性。乳腺癌细胞系对CX-4945敏感性最广泛，其EC50为1.71-20.01 μM。CX-4945的抗恶性细胞增生活性与CK2α mRNA和蛋白水平对应，但是与CK2α'催化亚基、调整CK2β亚族和PI3K/Akt 或 PTEN突变状态无关。CX-4945通过抑制CK2直接阻断Akt第129位丝氨酸的磷酸化作用来抑制PI3K/Akt信号通路，而不是通过抑制激活的PTEN起作用。用CX-4945处理可以引起磷酸化p21 (T145)减少，而p21和p27整体水平则会升高，同时诱导caspase 3/7活性。用CX-4945处理会诱导BT-474细胞阻断在细胞周期的G2/M期和BxPC-3细胞阻断在G1期。CX-4945会抑制HUVEC的增殖、迁移及血管新生，其IC50分别是5.5 μM, 2 μM和4 μM。在含氧量低的情况下BT-474和BxPC-3细胞用CX-4945处理，能阻断p53和pVHL下调，降低HIF-1α的转录活性^[1]。在Jurkat细胞中CX-4945能有效抑制内源细胞内的内源CK2的活性，其IC50是0.1 μM ^[2]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A431	NVfiTlh3TnWwY4Tpc44hSXO\|YYm=	MkLtNVAh\|ryP	NWXHTYh{OzBibXnu		NVW4bo45[XS2ZX71ZZRmeyCSSUPLMWFsfC2vVF;SJJNq\26jbHnu[y=>	NVjITWx2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzPFc6QDhpPkKyN\|g4QTh6PD;hQi=>
H2170	NEW2fnpHfW6ldHnvckBCe3OjeR?=	MmXYNVAh\|ryP	Mkn6N\|AhdWmw		MULheJRmdnWjdHXzJHBKO0tvQXv0MY1VV1Jic3nncoFtcW6p	M2m1U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i3PVg5Lz5{MkO4O\|k5QDxxYU6=
A431	MkfCSpVv[3Srb36gRZN{[Xl?	M32wSlExKM7:TR?=	NHzpeVY1NTJ2IHi=		Mmrl[Y5p[W6lZYOgZZBweHSxc3nzJJdqfGhiZYLsc5Rqdmmk	NWXhW3hrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzPFc6QDhpPkKyN\|g4QTh6PD;hQi=>
H2170	NHjmN2dHfW6ldHnvckBCe3OjeR?=	MWOxNEDPxE1?	NXL1bVNFPC1{NDDo		MWTlcohidmOnczDhdI9xfG:\|aYOge4l1cCCncnzveIlvcWJ?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN6N{m4PEc,OjJ\|OEe5PFg9N2F-
LNCap	NFHaW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:zUYt3OC1\|MDFOwG0>	M3;iUVQh\A>?		NVn2R4xOUUN3ME20MlU6yqEQvF2=	M3i1R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOyN\|E3Lz5{MkizNlMyPjxxYU6=
A549	NEK3NWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXGwMVMxKM7:TR?=	M2\zWlczKGh?	NXjZ[VlKTE2VTx?=	MmnlTWM2OD12LkG1JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?=	NVv0XoRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVE1PDNpPkKzOlUyPDR\|PD;hQi=>
H1299	NH7oZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDyNE0{OCEQvF2=	MnS5O\|IhcA>?	NVLub4poTE2VTx?=	NGL4OnlKSzVyPUGuPFAh\|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	NFK4dnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[1NVQ1Oyd-MkO2OVE1PDN:L3G+
A549	NEDWSHpHfW6ldHnvckBCe3OjeR?=	NILjOVgyNzFyIN88US=>	NFfMe\|M1QCCq	NIP1UGpFVVOR	NF3ZOItt\WGmczD0c{BiKGSxc3Wt[IVx\W6mZX70JIRm[3KnYYPlJIlvKE6xdHPoJJJmeG:{dHXyJIFkfGm4aYT5	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3MUS0N{c,OjN4NUG0OFM9N2F-
S-LAMA84	NEDzfodHfW6ldHnvckBCe3OjeR?=	M1zwTlPDqM7:TR?=	MU[yOEBp	MnjESG1UVw>?	MoX4doVlfWOnczDDT\|Ih[WO2aY\peJk>	NHjvZ\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxNlExQSd-MkSwNVIyODl:L3G+
R-LAMA84	M1LmdGZ2dmO2aX;uJGF{e2G7	M4rh[FPDqM7:TR?=	NXLkell3OjRiaB?=	M{jSfmROW09?	NXLoWFN1emWmdXPld{BEUzJiYXP0bZZqfHl?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzMkGwPUc,OjRyMUKxNFk9N2F-
S-LAMA84	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUeyMlUuOTBizszN	NHLUUno1QCCq	MmPMSG1UVw>?	MU\pcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	NF\VVnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxNlExQSd-MkSwNVIyODl:L3G+
R-LAMA84	MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVKyMlUuOTBizszN	NV63XVJVPDhiaB?=	MoPmSG1UVw>?	MmjPbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	NX20cnM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVIyODlpPkK0NFEzOTB7PD;hQi=>
A549	NUTFRW5MTnWwY4Tpc44hSXO\|YYm=	Mor3NVAh\|ryP	MUSxNk8zPC92ODDo		MlnCbY5pcWKrdIOgWGdHNc7{MT3pcoR2[2WmIH3p[5JifGmxbjDhcoQhcW64YYPpc44>	NFHCNmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECyN\|k{QCd-MkSwNlM6Ozh:L3G+
A549	M3Oyc2Z2dmO2aX;uJGF{e2G7	NIm3SVU{KM7:TR?=	NW\6XZlIPDhiaB?=		M{Hrb4lvcGmkaYTzJHRITi4QskGtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKFOvYXSgZY5lKGW6cILld5Nqd25ib3[gV45icWxiYX7kJHR4cXO2	NUD3TXI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNlM6OzhpPkK0NFI{QTN6PD;hQi=>
U-266	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDmTWk{OC12MDFOwG0>	MVy0PEBp		MXHJR\|UxRTF7LkigxtVOyqB?	NYLzV5lwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFY1QTRpPkK0NFg3PDl2PD;hQi=>
INA-6	NGjNU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\1NE01OCEQvF2=	MWe0PEBp		NFnwbXhKSzVyPUKuOFIhyrWP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6NkS5OEc,OjRyOE[0PVQ9N2F-
Jeko-1	M1yyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7PPIxLOC12MDFOwG0>	NUH6eoU1PDhiaB?=		MVLJR\|UxRTJwNDFCuW3DqA>?	NI[0OHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4OlQ6PCd-MkSwPFY1QTR:L3G+
Rec-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\5U3gxNTRyIN88US=>	MWG0PEBp		M1HITGlEPTB;MT60OkDDvU4EoB?=	NHjGWJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4OlQ6PCd-MkSwPFY1QTR:L3G+
Jurkat	M2n2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPGUVI1OS1zMDFOwG0>	MWS0PEBp		NHy1dmpKSzVyPUSuPUDPxE1?	NUnOflc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVMxOjRpPkK0NlU{ODJ2PD;hQi=>
CEM-R	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3uzNlEuOTBizszN	NFvkN3E1QCCq		M2\pdmlEPTB;NDFOwG0>	NFe4S3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK1N\|AzPCd-MkSyOVMxOjR:L3G+
CEM-S	M{\MW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorINU0yOCEQvF2=	MVi0PEBp		M2r5XGlEPTB;ND62JO69VQ>?	M1nVWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkWzNFI1Lz5{NEK1N\|AzPDxxYU6=
MOLT-4	M{T4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;wNU0yOCEQvF2=	MU[0PEBp		M1LBO2lEPTB;NT63JO69VQ>?	NWjkfppxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVMxOjRpPkK0NlU{ODJ2PD;hQi=>
PF-382	NFPzb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvLUZFROS1zMDFOwG0>	MmDNOFghcA>?		NXL6UWdrUUN3ME20MlUh\|ryP	MmXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NUOwNlQoRjJ2MkWzNFI1RC:jPh?=
ALL-SIL	NXnjeZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkW3NU0yOCEQvF2=	MnfFOFghcA>?		MmfJTWM2OD13Lkeg{txO	NF\oSpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK1N\|AzPCd-MkSyOVMxOjR:L3G+
HPB-ALL	M1HUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fHZ\|EuOTBizszN	M1rod\|Q5KGh?		Mn\ITWM2OD14LkGg{txO	M{TT[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkWzNFI1Lz5{NEK1N\|AzPDxxYU6=
DND-41	M1:1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHuNU0yOCEQvF2=	NV;ofpU6PDhiaB?=		MmLSTWM2OD17IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
ALL-SIL	M3PVfmFxd3C2b4Ppd{BCe3OjeR?=	NEjEZ402KM7:TR?=	NYr0bI54OjRxNEigbC=>		MkS5bY5lfWOnczDhdI9xfG:\|aYO=	MnTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NUOwNlQoRjJ2MkWzNFI1RC:jPh?=
DND-41	MWjBdI9xfG:\|aYOgRZN{[Xl?	NWjT[GJ4PSEQvF2=	MV6yOE81QCCq		MnHlbY5lfWOnczDhdI9xfG:\|aYO=	MkTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NUOwNlQoRjJ2MkWzNFI1RC:jPh?=
MOLT-4	M1[0RmFxd3C2b4Ppd{BCe3OjeR?=	M3qxUlUh\|ryP	M3;wZlI1NzR6IHi=		MmG3bY5lfWOnczDhdI9xfG:\|aYO=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3M{CyOEc,OjR{NUOwNlQ9N2F-
C2C12	NYf6dpJ1TnWwY4Tpc44hSXO\|YYm=	MUKzJO69VQ>?	NYXVPIlDOTJxMkSvOFghcA>?		Mn7LbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gc5N1\W:lbHHzeEBlcW[oZYLlcpRq[XSrb36gcYFzc2W{czDhcoQhSWu2IIDoc5NxcG:{eXzheIlwdg>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7M{CxNUc,OjR{OUOwNVE9N2F-
Nalm6	MUXGeY5kfGmxbjDBd5NigQ>?	NELCTJYyOC9{MDFOwG0>	M3PpVVI1KGh?		NVnnXY1VemW\|dXz0d{BqdiCmZXPy[YF{\WRiUGTFUkBxcG:\|cHjvdplt[XSrb36gZZQhfGinIFPLNkB1[XKpZYSgdoV{cWS3ZTDTN\|gxKGGwZDDjc45kd22rdHHueEBld3ewcnXneYxifGmxbjDv[kBRXEWQIIDyc5RmcW5iZYjwdoV{e2mxbh?=	M4TwcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[xO\|kzLz5{NEW2NVc6OjxxYU6=
SUP-B15	MlnzSpVv[3Srb36gRZN{[Xl?	M2X4WlExNzJyIN88US=>	MlH5NlQhcA>?		MUjy[ZN2dHS\|IHnuJIRm[3KnYYPl[EBRXEWQIIDoc5NxcG:{eXzheIlwdiCjdDD0bIUhS0t{IIThdodmfCC{ZYPp[JVmKFN\|OECgZY5lKGOxbnPvcYl1[W62IHTve45z\We3bHH0bY9vKG:oIGDUSW4heHKxdHXpckBmgHC{ZYPzbY9v	NIDZd249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2NVc6Oid-MkS1OlE4QTJ:L3G+
Nalm6	MoLnRZBweHSxc3nzJGF{e2G7	M4HQXVYwOTBizszN	NGrmcXI1QCCq		MW\pcoR2[2W\|IHHwc5B1d3Orcx?=	M4rKUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[xO\|kzLz5{NEW2NVc6OjxxYU6=
SUP-B15	M3;EUmFxd3C2b4Ppd{BCe3OjeR?=	MkfEOk8yOCEQvF2=	NH2yOGE1QCCq		MYLpcoR2[2W\|IHHwc5B1d3Orcx?=	NWmxNpJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlE4QTJpPkK0OVYyPzl{PD;hQi=>
ARPE-19	MoXLT4lv[XOnIFHzd4F6	MXi1M\|ExNzJyIN88US=>	M1\jU\|I1NzR6IHi=		NV60T4Q5cW6qaXLpeJMhS0t{IHvpcoF{\SCjY4Tpeol1gSCjdDDhJINwdmOnboTyZZRqd25ib3[gOeKh\|ryP	M2HwTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nki2NFgxLz5{NE[4OlA5ODxxYU6=
ARPE-19	M2LaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmD0NVAh\|ryP	MnvkNlQuQTZiaB?=	NX7EZo9vTE2VTx?=	NXrI[WR[cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>?	MnzjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OE[wPFAoRjJ2Nki2NFgxRC:jPh?=
HCT116	M1HWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlX3NVAh\|ryP	Mo\vNlQuQTZiaB?=	M1u3RWROW09?	MUfpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	NF3sRYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4OlA5OCd-MkS2PFYxQDB:L3G+
ARPE-19	NXvYfmxHTnWwY4Tpc44hSXO\|YYm=	M1XQd\|ExKM7:TR?=	M13LclQhcA>?	NUe1c\|VCTE2VTx?=	NVu3[Ih4[2G3c3XzJGVTNXO2cnXzd{Bz\XOyb37z[UBwfmW{IITo[UBxNWWLRkNOtUBjemGwY3isJIJ2fCCmb3XzJI5wfCCrbnT1Z4UhS0iRUNMg	MnvmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OE[wPFAoRjJ2Nki2NFgxRC:jPh?=
HCT116	NGfP[2hHfW6ldHnvckBCe3OjeR?=	NXHUfpQ2OTBizszN	MljMOEBp	NVv1RoFpTE2VTx?=	MX;jZZV{\XNiRWKtd5Rz\XO\|IILld5BwdnOnIH;2[ZIhfGinIICt[WlHOs7zIHLyZY5kcCxiYoX0JIRw\XNibn;0JIlv\HWlZTDDTG9RyqB?	NWfNPGp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFYxQDBpPkK0Olg3ODhyPD;hQi=>
HCT116	NUnSXXYxSXCxcITvd4l{KEG\|c3H5	NEfi[W8yOCEQvF2=	MVuyOE81QCCq	NU[2XWpkTE2VTx?=	M3;vOIlv\HWlZYOgZZBweHSxc3nz	M1Pk[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nki2NFgxLz5{NE[4OlA5ODxxYU6=
MDA-MB-231	MnTLSpVv[3Srb36gRZN{[Xl?	M2rMflIwPS9zMDFOwG0>	NHHFWIs1KGh?		NUHtc\|hv\GWlcnXhd4V{KHSqZTDjc45{fGm2dYTpeoUheGixc4Doc5J6dGG2aX;uJI9nKGKxdHigJJAuWzV{OT3wOlUh[W6mIICtV\|EzQS2Da4S=	M3H5WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWzO\|I2Lz5{NUG1N\|czPTxxYU6=
MDA-MB-231	Mn71SpVv[3Srb36gRZN{[Xl?	MVyyM\|UwOTBizszN	M4PkWFQhcA>?		NYXtNVBlcW6qaXLpeJMhe2W{aX7lJFUzQSCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBmgHC{ZYPzbY9vKG:oIFnMMVYtKEmOLUi=	NV7KRVBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVM4OjVpPkK1NVU{PzJ3PD;hQi=>
U87-MG	M2TDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXmxM\|UwOTBizszN	MnvUNlQwPDhxN{KgbC=>	MXHEUXNQ	MlfNbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[m:2aDDjc45k\W62cnH0bY9vKGGwZDD0bY1mKGSncHXu[IVvfGy7	Mmj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NEG4PVcoRjJ3MkSxPFk4RC:jPh?=
UM-SCC-1	NVrSdmR2S2yxbn;n[Y5q[yCDc4PhfS=>	M4PORVAvPS13IN88US=>	MnrBNVQh\A>?	Mn72SG1UVw>?	M2PWNOKhcW6qaXLpeJMh[2yxbn;n[Y5q[yC\|dYL2bZZidCCjbnSgd5Bp\XKnIH\vdo1ifGmxbh?=	NGDjTog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3PVAyPid-MkWzO\|kxOTZ:L3G+
UM-SCC-46	MVfDcI9vd2enbnnjJGF{e2G7	NHG1UHIxNjVvNTFOwG0>	MnLhNVQh\A>?	M13jbGROW09?	M4\jcuKhcW6qaXLpeJMh[2yxbn;n[Y5q[yC\|dYL2bZZidCCjbnSgd5Bp\XKnIH\vdo1ifGmxbh?=	NHXjVVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3PVAyPid-MkWzO\|kxOTZ:L3G+
H28	M2LsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LjfVAvODFvM{Cg{txO	M2rwU\|czKGh?	M1rJd2ROW09?	MV3JR\|UxRTdwMjFOwG0>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{MkC4NUc,OjV2MkKwPFE9N2F-
H2052	NVjDcmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVqwMlAyNTNyIN88US=>	NF;xd2M4OiCq	MXvEUXNQ	NYftN4txUUN3ME2yMlAh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{MkC4NUc,OjV2MkKwPFE9N2F-
PC9/GR	NH;HW2pHfW6ldHnvckBCe3OjeR?=	MXe1JOK2VQ>?	NH;FdZU1QCCq		MXHpcoR2[2W\|IHH1eI9xcGGpeR?=	M1Lo[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEi2OFA6Lz5{NUS4OlQxQTxxYU6=
PC9/ER	M372bWZ2dmO2aX;uJGF{e2G7	NYrPUlM4PSEEtV2=	M1PCRVQ5KGh?		NFToOYpqdmS3Y3XzJIF2fG:yaHHnfS=>	M1\SclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEi2OFA6Lz5{NUS4OlQxQTxxYU6=
H1299	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXixM\|UwOTBizszN	MnG5O\|IhcA>?		MXHpcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3MEOwPEc,OjV5NUCzNFg9N2F-
Calu-1	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3xdIlSOS93L{GwJO69VQ>?	MVS3NkBp		MX\pcohq[mm2czDj[YxtKGe{b4f0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	M3;2Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{WwN\|A5Lz5{NUe1NFMxQDxxYU6=
H358	NHHtUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3G0TlEwPS9zMDFOwG0>	M4nTZlczKGh?		NGXYZmhqdmirYnn0d{Bk\WyuIHfyc5d1cCClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3MEOwPEc,OjV5NUCzNFg9N2F-
H1299	NGnLd2pCeG:ydH;zbZMhSXO\|YYm=	M3\RdFExKM7:TR?=	NW\6dnlYPzJiaB?=		MUjpcoR2[2W\|IHHwc5B1d3Orcx?=	NUTVOXNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVA{ODhpPkK1O\|UxOzB6PD;hQi=>
Calu-1	MYLBdI9xfG:\|aYOgRZN{[Xl?	NV3uS2R4OTBizszN	M3LUVFczKGh?		M2r5folv\HWlZYOgZZBweHSxc3nz	M3jYTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{WwN\|A5Lz5{NUe1NFMxQDxxYU6=
H358	MUPBdI9xfG:\|aYOgRZN{[Xl?	M1LUNlExKM7:TR?=	NXX4RZBJPzJiaB?=		NEfZU4xqdmS3Y3XzJIFxd3C2b4Ppdy=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3MEOwPEc,OjV5NUCzNFg9N2F-
NU-DUL	M4rUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXqSXA2NTJ3IN88US=>	NIXCc4Q1QCCq		Mkf5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	M{i0XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i4NlY6Lz5{NUe4PFI3QTxxYU6=
Oci Ly 3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{SwSlUuOjVizszN	MnzIOFghcA>?		M3vNNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	M{X3dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i4NlY6Lz5{NUe4PFI3QTxxYU6=
Oci Ly 10	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVm1MVI2KM7:TR?=	M{jz[FQ5KGh?		NF;ZRWRqdmirYnn0d{Bk\WyuIHfyc5d1cCClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6	M2LOfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i4NlY6Lz5{NUe4PFI3QTxxYU6=
Oci Ly 1	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVW1MVI2KM7:TR?=	M4PRclQ5KGh?		MmflbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	NUDnOYtHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFgzPjlpPkK1O\|g5OjZ7PD;hQi=>
Oci Ly 18	NG\Ve2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NED3N3k2NTJ3IN88US=>	M1T3WFQ5KGh?		MmjtbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=>	NGfoUVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PFI3QSd-MkW3PFgzPjl:L3G+
Oci Ly 19	NEHOOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXG1MVI2KM7:TR?=	MorPOFghcA>?		M{XDc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	NHXweYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PFI3QSd-MkW3PFgzPjl:L3G+
Raji	M4HMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVq1MVI2KM7:TR?=	M3T4R\|Q5KGh?		M{m0S4lvcGmkaYTzJINmdGxiZ4Lve5RpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	NWfy[WhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFgzPjlpPkK1O\|g5OjZ7PD;hQi=>
UM-SCC1	M2O1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzRVogxNjFvM{Cg{txO	MlfXNU02KGR?		NYfUb\|lIUUN3ME20MlEh\|ryP	NH;kR\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5PFA3OSd-MkW3PVgxPjF:L3G+
UM-SCC46	NH;KUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHuydnIxNjFvM{Cg{txO	M{npdlEuPSCm		MYHJR\|UxRTNwNDFOwG0>	MoDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUiwOlEoRjJ3N{m4NFYyRC:jPh?=
UM-SCC1	M4f2eGZ2dmO2aX;uJGF{e2G7	NF\IdGkxNjVxND:xNEDPxE1?	NGfhO3E4OiCq		NXXiNVd2\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gUmYuzLiELDDCZ4wuYExiYX7kJJVxNXKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCyNUOsJJAzOSxiQWCtNUBidmRiSVytPEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7OEC2NUc,OjV5OUiwOlE9N2F-
UM-SCC46	NFe4WnFHfW6ldHnvckBCe3OjeR?=	MnzLNE42NzRxMUCg{txO	MXy3NkBp		MUTkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCQRj5EvGItKEKlbD3YUEwheDV\|LDDwNlEtKEGSLUGgZY5lKHWyLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCLTD24JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	NX2zR4NWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVgxPjFpPkK1O\|k5ODZzPD;hQi=>
HEK293	Mn3iT4lv[XOnIFHzd4F6	NInhV2MxNjYEoN88US=>	MVSxOUBucW5?	NHnUeXVFVVOR	NX3jc2NXemWmdXPld{BEUzJia3nuZZNmKGGldHn2bZR6	NIDENWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4O\|YzPid-MkW4PFc3OjZ:L3G+
Hela	M3zyUmtqdmG\|ZTDBd5NigQ>?	M4\ue\|AvPcLizszN	MYmxOUBucW5?	MUHEUXNQ	M2HNO5Jm\HWlZYOgR2szKGurbnHz[UBi[3Srdnn0fS=>	MlHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEe2NlYoRjJ3OEi3OlI3RC:jPh?=
LAMA84	NHfFVmFMcW6jc3WgRZN{[Xl?	M3nqWlAvPcLizszN	NYjXZmdWOTVibXnu	M{PjbWROW09?	NHrYV4xz\WS3Y3XzJGNMOiCtaX7hd4Uh[WO2aY\peJk>	MlPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEe2NlYoRjJ3OEi3OlI3RC:jPh?=
HEK293	MXrGeY5kfGmxbjDBd5NigQ>?	NFq1OGs{KM7:TR?=	NUXtc3NyPSCq	MXrEUXNQ	M1PSRmNMOiCyaH;zdIhwenmuYYTld{BmUUZ\|ajDheEBU\XJzMke=	NIHpZVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4O\|YzPid-MkW4PFc3OjZ:L3G+
HDMEC	M3fDSWtqdmG\|ZTDBd5NigQ>?	M4q2fFEuPTBizszN	M3:1OlUhcA>?	NGLT[WdFVVOR	MY\k[YNz\WG\|ZYOgR2szKGurbnHz[UBi[3Srdnn0fUB4cXSqb4X0JIFn\mWldHnu[{Bk\WyuII\pZYJqdGm2eR?=	NIXr[m49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG4PVU5Pid-Mk[xPFk2QDZ:L3G+
HDMEC	M2LoS2Z2dmO2aX;uJGF{e2G7	MWm1NEDPxE1?	MW[xM\|UhcA>?	M{fKVWROW09?	NUe0cXQx\GWlcnXhd4V{KHSqZTDueYNt\WG{IIPp[45idCCxZjDwbI9{eGixconsZZRm\CCyNkWgbY4hXE6ILd8xMZN1cW23bHH0[YQhUESPRVRCpC=>	MnTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOEm1PFYoRjJ4MUi5OVg3RC:jPh?=
A549	MlLRSpVv[3Srb36gRZN{[Xl?	MlXRN{8yOMLizszN	MmDpOFghcA>?		Mluzd5VxeHKnc4Pld{B1cGVibXnjdo9xcWyuYYKtbY5lfWOnZDDlfJBz\XO\|aX;uJI9nKHBvRlHL	MoPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|MUi4NFAoRjJ4M{G4PFAxRC:jPh?=
platelets	NXjiemNXU2mwYYPlJGF{e2G7	NXLZ[XVJOS93L{GwJO69VQ>?	NX\Xd5RbOC53IHi=	NUSxNlk{TE2VTx?=	MXry[YR2[2W\|IFPLNkBscW6jc3WgZYN1cX[rdImgZY5lKHCuYYTlcIV1KGGpZ4Ll[4F1cW:w	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN6MUSzO{c,OjZ\|OEG0N\|c9N2F-
HDMEC	MmnmT4lv[XOnIFHzd4F6	MVWwMlI2NzBwNT:xJO69VQ>?	NH7ZWVAzPCCq	NEXGSWZFVVOR	NV\KUY5uemWmdXPld{BEUzJia3nuZZNmKGGldHn2bZR6NCC4V1[g[ZhxemW\|c3nvckBidmRic3XjdoV1cW:w	NH\XTnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO4NVQ{Pyd-Mk[zPFE1Ozd:L3G+
HDMEC	MWfGeY5kfGmxbjDBd5NigQ>?	NUXrN4sxOC5{NT:wMlUwOSEQvF2=	MYWyOEBp	NHzQWlNFVVOR	NV3GTZZNemWmdXPld{BmgHC{ZYPzbY9vKG:oIG\DRW0uOSCkdYSgco91KEmFQV2tNS=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN6MUSzO{c,OjZ\|OEG0N\|c9N2F-
HDMEC	M2q2XGZ2dmO2aX;uJGF{e2G7	NYX3RmplOSEQvF2=	M1\uO\|I1KGh?	NIHwRnZFVVOR	MlWwZYZn\WO2czDzeYJk\WyudXzhdkBtd2OjbHn6ZZRqd25ib3[gUmZCXGNzIHHu[EBxcG:\|cHjvMZA3PQ>?	MnvMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OEG0N\|coRjJ4M{ixOFM4RC:jPh?=
Jurkat	NWL2fm9CTnWwY4Tpc44h[XO\|YYm=				M1HRRWlvcGmkaYTpc44hd2ZiQ1uyJIlvKGi3bXHuJGp2emujdDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFupYX3tZVM{WF2DVGCgbY5kd3Kyb4LheIlwdiCrboTvJJN2[nO2cnH0[UBjgSCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkGg{txONg>?	NWq4T2tlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
MIAPaCa2	MmDGRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWK0JIRigXN?		Mn;qRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPSVHQZWNiOiClZXzsd{Bi\nSncjC0JIRigXNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCxMlEh\|ryPLh?=	NWnZN2FGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
PC3	MmHpRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXTz[WllPCCmYYnz		MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjZoTldkA1KGSjeYOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAzNjFizszNMi=>	MomzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{S0N\|QoRjJzMUe0OFM1RC:jPh?=
HCT116	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVXIWFVvPCCmYYnz		NHXY[ZZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC0JIRigXNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCyMlIh\|ryPLh?=	NUnCNYpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
H1299	MlK0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkT1OEBl[Xm\|		M4HPUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSEGyPVkh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMj60JO69VS5?	NWHpR3dVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
Jurkat	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnPkOEBl[Xm\|		MkjDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCMdYLrZZQh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMj61JO69VS5?	MlL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{S0N\|QoRjJzMUe0OFM1RC:jPh?=
A549	MmnuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWLSbmg4PCCmYYnz		MoLsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDNizszNMi=>	NHzpZnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO\|Q1OzR:L3G+
A375	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NXTYU281PCCmYYnz		NW[wOYJxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEOuPUDPxE1w	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5NESzOEc,OjFzN{S0N\|Q9N2F-
BxPC3	NGXZfYxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NX3JU406PCCmYYnz		NIDJSFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFL4VGM{KGOnbHzzJIFnfGW{IESg[IF6eyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IESuOEDPxE1w	NX\DcoxERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
LNCAP	NH7ZTlNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1njOlQh\GG7cx?=		MkHaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOTlPBVEBk\WyuczDh[pRmeiB2IHThfZMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSB2Lkeg{txONg>?	NWLZNnZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|Q1OzRpPkKxNVc1PDN2PD;hQi=>
K562	MoLzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWq3Z2w4PCCmYYnz		MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hPS5\|IN88UU4>	NG\UcnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO\|Q1OzR:L3G+
MDA-MB-231	MkHlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnTnOEBl[Xm\|		M4DjOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjZoTldkA1KGSjeYOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUA3NjRizszNMi=>	MoCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{S0N\|QoRjJzMUe0OFM1RC:jPh?=
MCF7	NHnlWoZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYS0JIRigXN?		NEnRUVNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNDDkZZl{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iOD65JO69VS5?	MnqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{S0N\|QoRjJzMUe0OFM1RC:jPh?=
Hs 578T	M1v6NGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M33LclQh\GG7cx?=		M4XROWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIOgOVc5XCClZXzsd{Bi\nSncjC0JIRigXNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCxN{4yKM7:TT6=	NFq5XHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3OFQ{PCd-MkGxO\|Q1OzR:L3G+
HCT116	NEe1bYtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIPNNVE4OiCqcoO=		MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iNT6yJO69VS5?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|OUSzN{c,OjJ\|M{m0N\|M9N2F-
MCF7	MmnURY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkPPO\|IhcHK\|		MmXlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB4LkWg{txONg>?	NIDuZ5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzPVQ{Oyd-MkKzN\|k1OzN:L3G+
A549	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIXnfHk4OiCqcoO=		M4j3NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iOD6yJO69VS5?	NH7oWIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzPVQ{Oyd-MkKzN\|k1OzN:L3G+
MV4-11	MkjoRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NV3sZo5qOSC2bzCzJIRigXN?		M1e4SmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJIFnfGW{IEGgeI8hOyCmYYnzJIJ6KE2WUzDhd5NigSxiQ1O1NEA:KDNizszNMi=>	NHzr[mM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exNVg{Oid-MkO3NVE5OzJ:L3G+
U937	NXvUUZZjSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHftXHQyKHSxIEOg[IF6ew>?		Mn;QRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXOUO3JINmdGy\|IHHmeIVzKDFidH:gN{Bl[Xm\|IHL5JG1VWyCjc4PhfUwhS0N3MDC9JFQvOiEQvF2u	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdzMUizNkc,OjN5MUG4N\|I9N2F-
Jurkat	NW\zUlZ5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWW2b\|FtOSC2bzCzJIRigXN?		MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEq3cnvheEBk\WyuczDh[pRmeiBzIITvJFMh\GG7czDifUBOXFNiYYPzZZktKEOFNUCgQUA1NjVizszNMi=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdzMUizNkc,OjN5MUG4N\|I9N2F-
K562	M4TadWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUDmUoNYOSC2bzCzJIRigXN?		NYW4SI9RSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEGgeI8hOyCmYYnzJIJ6KE2WUzDhd5NigSxiQ1O1NEA:KDdizszNMi=>	MlnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUG4N\|IoRjJ\|N{GxPFMzRC:jPh?=
Sf9	NIi3NWZHfW6ldHnvckBie3OjeR?=				MYPJcohq[mm2aX;uJI9nKEOGS{KvZ5lkdGmwIFWgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KHW\|aX7nJIhqe3SxbnWgTFEh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFupYX3tZVM{WF2DVGCsJGlEPTBiPTCxMlgh\|ryPLh?=	NVzvbYRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFE6QDZpPkK0OlgyQTh4PD;hQi=>
A549	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=		MlXDO\|IhcHK\|		MmDER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBESzVyIE2gPU46KM7:TT6=	Mmr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6NUCzO\|YoRjJ4OEWwN\|c3RC:jPh?=
Sf21	Ml7KSpVv[3Srb36gZZN{[Xl?		NVPCWVVKQTBibXnudy=>		NY\lTllEUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBPNXSncn3pcoFtKEirc{[teIFo\2WmIFPLNoFteGijIHX4dJJme3OnZDDpckBU\jJzIHnud4VkfCClZXzsd{B2e2mwZzDDT\|J1cWSnIHHzJJN2[nO2cnH0[UB1emWjdHXkJIZweiB{MDDtbY5{KG2nYYP1doVlKGGodHXyJFkxKG2rboOgbY4heHKnc3XuZ4Uhd2ZiTXfDcFIh[nliY3HsbZBmeiCvb3LpcIl1gSC\|aHnmeEBie3OjeTygTWM2OCB;IECuNFA{KM7:TT6=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV3OUK3PEc,Ojl3NUmyO\|g9N2F-
Vero E6	M2m1eWFvfGm4aYLhcEBie3OjeR?=		MlXXOFghcA>?		NWPucmh6UUN3MDDmc5Ih[W62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhW0GUUz3Dc3YuOiCrbjD0bIUhXmW{bzDFOkBk\WyuIHzpcoUh[XRiNEigbEBjgSCrbX31co9ndHWxcnXzZ4Vv[2VvYnHz[YQh[XO\|YYmgLIRmfGWldHnu[{B1cGVidnnyZYwhVlBicILveIVqdiCrbjD0bIUhdnWlbHX1d{Bw\iC2aHWgWoVzdyCHNjDj[YxteylwLDDJR\|UxKD1iMz64PVA1PSEQvF2u	NIrMOIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MkO1N\|g2QSd-M{KzOVM5PTl:L3G+
A549	M4rwUGZ2dmO2aX;uJIF{e2G7	M1HlRlMxKHWP	NUnnT2REPDhiaILz		M{nJVGlvcGmkaYTpc44hd2ZiQ1uyMY1m\GmjdHXkJG1OWDJiYXP0bZZifGmxbjDpckBpfW2jbjDBOVQ6KGOnbHzzJIF1KDNyIIXNJIFnfGW{IES4JIhzeyCkeTDn[YxifGmwLYr5cY9oemGyaIm=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzMkGyOEc,OjRyMUKxNlQ9N2F-
A549	NVvi[nJPTnWwY4Tpc44h[XO\|YYm=	MYGxNEB2VQ>?	NXHSTJNYOTVidH:gN\|AhdWmwcx?=		MX;Jcohq[mm2aX;uJI9nKEONMj3t[YRq[XSnZDDFVmsheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGE2PDliY3XscJMh[XRiMUCgeW0h[W[2ZYKgNVUhfG9iM{CgcYlveyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k	MofZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNlQoRjJ2MEGyNVI1RC:jPh?=
A549	MlnuSpVv[3Srb36gZZN{[Xl?	NILWfmoyKHSxIEGwJJVO	NXjYSmJtOjRiaILz		M321ZmlvcGmkaYTpc44hd2ZiQ1uyMY1m\GmjdHXkJG1VOS2PTWCg[ZhxemW\|c3nvckBqdiCqdX3hckBCPTR7IHPlcIx{KGG2IEGgeI8hOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzMkGyOEc,OjRyMUKxNlQ9N2F-
A549	Ml;wSpVv[3Srb36gZZN{[Xl?	NXPKV\|U6OTBidV2=			NX;ycllmUW6qaXLpeIlwdiCxZjDDT\|IudWWmaXH0[YQhTVKNIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCDNUS5JINmdGy\|IHH0JFExKHWPIHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	Mm[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUKxNlQoRjJ2MEGyNVI1RC:jPh?=
A549	NVvqdYhrTnWwY4Tpc44h[XO\|YYm=	NEPvNIEyOCC3TR?=	MVGyOEBpenN?		MnvtTY5pcWKrdHnvckBw\iCFS{KtcYVlcWG2ZXSgRWtVKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBCPTR7IHPlcIx{KGG2IEGwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RibXX0bI9l	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzMkGyOEc,OjRyMUKxNlQ9N2F-
A549	NIrtRm1HfW6ldHnvckBie3OjeR?=	MX6xNEB2VQ>?	M3XIfFQhfG9iMkSgbJJ{		MXPJcohq[mm2aX;uJI9nKEONMj3t[YRq[XSnZDDBT3QheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGE2PDliY3XscJMh[XRiMUCgeW0h[W[2ZYKgOEB1dyB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?=	NHrpZXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxNlEzPCd-MkSwNVIyOjR:L3G+
U-2 OS	MlrEdWhVWyCjc4PhfS=>				Mo[0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	NVLKO41yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	NFvKSVJyUFSVIHHzd4F6				M1nvbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	M2DRTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	MV;xTHRUKGG\|c3H5				NVuxPVdpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	Mn7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	M2n4S5FJXFNiYYPzZZk>				MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NV3qdJh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NWDmWpo3eUiWUzDhd5NigQ>?				NWDSV3NNeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	M2LIRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MmDZdWhVWyCjc4PhfS=>				M322[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	M1rlPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NYPyWHlQeUiWUzDhd5NigQ>?				NX;vU3E4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	M4XydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	M{Pz[JFJXFNiYYPzZZk>				NVnDO4cyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	M1rYOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MmSwdWhVWyCjc4PhfS=>				M{fwU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	MoXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MoDRdWhVWyCjc4PhfS=>				M4\ncJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	Mn;GdWhVWyCjc4PhfS=>				NIT4[WRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	M{LkVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	M1rM[pFJXFNiYYPzZZk>				NI\5OmlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	M4e5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NHz6PGxyUFSVIHHzd4F6				MWrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NYPzUZdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NFzvWYhyUFSVIHHzd4F6				M2LpXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	Mn;6dWhVWyCjc4PhfS=>				NHzy[FlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MojHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NWiycIIzeUiWUzDhd5NigQ>?				Ml3rdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NHrBd4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	NUPEXIs4eUiWUzDhd5NigQ>?				NXTuc5I6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	NYDqUXV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-S6K1(T389) / S6K1 / p-S6(S235/236) / S6; PubMed: 30683840 Cell Death Dis DLD-1 cells were incubated with 25 μM silmitasertib for 16 h. The levels of the indicated proteins were analyzed by western blot. p-AKT(S129) / p-AKT(T308) / p-AKT(S473) / AKT / p-ERK / ERK / TP53 / p-p21(Th145) / p21 / Bcl-xl; PubMed: 25798061 Int J Biol Sci CX-4945 altered PI3K/AKT/Bcl-XL, ERK/AP-1 and TP53/p21proteins in HNSCC. UM-SCC-1 (left) and UM-SCC-46 (right) cell lines were treated with 4 and 10 μM CX-4945, whole cell lysates were harvested 6 and 24 hours after treatment, and subjected to SDS-PAGE and Western blot of indicated proteins. β-action was used as a loading control. p-Smad2 (Cytosol) / Smad2/3 (Cytosol) / Smad2/3 (Nucleus) / Twist / Snail; PubMed: 24023938 PLoS One The effect of CX-4945 on TGF-β1-induced activation of Smad and expression of Snail and Twist was evaluated using Western blot analysis. Briefly, after 24 h serum starvation, A549 cells were treated with TGF-β1 (5 ng/ml) alone or in combination with CX-4945 in media containing 0.1% FBS for 48 h. Cytosolic and Nuclear fractions were obtained. Actin and histone H3 were used as internal control of cytosolic and nuclear fraction, respectively. The relative, normalized ratio between p-Smad2 and actin was presented.	30683840 25798061 24023938
Immunofluorescence	β-catenin; PubMed: 24023938 PLoS One Nuclear translocation of β-catenin and its inhibition by CX-4945 were confirmed by immunocytochemistry. Nuclei were counterstained with Hoechst 33342. All scale bars represent 20 µm. E-cadherin / Vimentin; PubMed: 24023938 PLoS One The effect of CX-4945 on the TGF-β1-induced expression of epithelial and mesenchymal markers was evaluated by immunocytochemistry. Briefly, after 24 h serum starvation, A549 cells were treated with TGF-β1 (5 ng/ml) alone or in combination with CX-4945 in media containing 0.1% FBS for 72 h. All scale bars represent 200 µm.	24023938
Growth inhibition assay	Cell viability; PubMed: 30316146 Transl Oncol CX-4945 decreases cell viability of HuCCT1, EGI-1, and Liv27 CCA cell lines in dose-dependent manner (IC50of 7.3, 9.5, and 9.4 μM, respectively) (A)	30316146

体内研究

在BT-474模型中，一天两次口服25 mg/kg或75 mg/kg的CX-4945，具有强效的抗癌活性，TGI分别为88% 和97%，每组实验动物9只中有2只其肿瘤的体积大小比初期的要减少50%。在BxPC-3模型中，一天两次用75 mg/kg的CX-4945处理，TGI为93%，在治疗期结束时，有3只动物没发现还有残留的肿瘤^[1]。在PC3异种移植的模型中，用25 mg/kg, 50 mg/kg或 75 mg/kg的CX-4945处理，能抑制肿瘤生长，TGI分别为19%, 40%和86%^[2]

激酶实验：^[2]	- 合并 CK2激酶实验: 将10 μL稀释缓冲液(ADB; 20 mM MOPS, pH 7.2, 25 mM β-磷酸甘油, 5 mM EGTA, 1 mM原钒酸钠和 1 mM 二硫苏糖醇)，10 μL多肽底物(RRRDDDSDDD, 溶于ADB，浓度1mM)和10 μL重组的人源CK2(ααββ-全酶, 25 ng溶于ADB)混合，加入10 μL CX-4945。加入10μLATP溶液(90% 75 mM MgCl ₂, 75 μM ATP (终浓度15 μM)溶于ADB; 10% [γ-³³P]ATP (储存1 mCi/100 μL; 3000 Ci/mM起始反应，30 ℃反应10分钟。用100 μL的0.75%的磷酸终止反应，然后转移到磷酸纤维素滤板上过滤。每个孔用0.75%磷酸洗5次，真空抽干5分钟，再每孔加入15 μL闪烁液，然后用Wallac荧光计数器检测残留的放射性。通过对0.0001 μM 到1 μM的8个浓度的CX-4945实验结果的检测，计算出IC50。
细胞实验：^[1]	- 合并 Cell lines: SKBr3, MDA-MB-453, BT-474, ZR-75-1, MDA-MB-231, MDA-MB-468, T47D, MCF 7, Hs578T, MDA-MB-361, UACC-812, 等等 Concentrations: 溶于 DMSO, 终浓度 ~100 μM Incubation Time: 4 天 Method: 在用药处理前，在合适的培养基中按每孔3000个细胞的浓度接种细胞培养24小时，然后用不同浓度的CX-4945处理细胞。接种悬浮细胞并处理相同的天数。接着孵育4天，加入Alamar Blue (20 μL, 体积比每孔10%)，然后于37℃孵育4-5小时。检测荧光，激发光为530-560 nm，放射光为590 nm。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 注射了BxPC-3 或BT-474细胞的免疫缺陷的雌鼠 Dosages: 25或75 mg/kg Administration: 每日两次口服 (Only for Reference)

参考文献

[4] Bliesath J, et al. Cancer Lett, 2012, 322(1), 113-118.

- 合并

溶解度 (25°C)

体外	DMSO	16 mg/mL (45.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Silmitasertib (CX-4945) SDF

分子量	349.77
化学式	C₁₉H₁₂ClN₃O₂
CAS号	1009820-21-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound (S2248) for in vivo uses?
回答：
For injection, CX-4945 can be dissolved in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 5mg/ml clearly. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm the solution in water bath at about 45-50℃. Then add PEG and Tween. After they mixed well, dilute with water. For oral gavage, CX-4945 can be dissolved in 1% CMC Na at 30mg/ml as a homogeneous suspension. This is a common formulation for oral gavage, and is convenience to prepare.

研究领域

产品类型

定制您的化合物库

Silmitasertib (CX-4945)

客户使用Selleck生产的Silmitasertib (CX-4945)发表文献79篇：

产品安全说明书

Casein Kinase抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Silmitasertib (CX-4945) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法